Free Trial
→ Finally… options made simple (From TradeWins) (Ad)tc pixel Free COIL Stock Alerts

Roquefort Therapeutics (COIL) Competitors

Roquefort Therapeutics logo
GBX 6.22 0.00 (0.00%)
As of 06:24 AM Eastern
Compare

COIL vs. TILS, VSN, SCLP, MPH, and 4BB

Should you buy Roquefort Therapeutics stock or one of its competitors? Roquefort Therapeutics's main competitors and comparable companies include Tiziana Life Sciences (TILS), Verseon (VSN), Scancell (SCLP), Mereo BioPharma Group plc (MPH.L) (MPH), and 4basebio (4BB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Roquefort Therapeutics compare to Tiziana Life Sciences?

Tiziana Life Sciences (LON:TILS) and Roquefort Therapeutics (LON:COIL) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

Tiziana Life Sciences has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Tiziana Life Sciences' return on equity of 0.00% beat Roquefort Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tiziana Life SciencesN/A N/A N/A
Roquefort Therapeutics -57,057.07%-18.71%-15.86%

1.8% of Roquefort Therapeutics shares are held by institutional investors. 36.3% of Roquefort Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Tiziana Life Sciences has higher earnings, but lower revenue than Roquefort Therapeutics. Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tiziana Life Sciences-£3.60M0.00N/A-£16.30N/A
Roquefort TherapeuticsN/AN/A-£1.52M-£20.24N/A

In the previous week, Tiziana Life Sciences' average media sentiment score of 0.00 equaled Roquefort Therapeutics'average media sentiment score.

Company Overall Sentiment
Tiziana Life Sciences Neutral
Roquefort Therapeutics Neutral

Summary

Tiziana Life Sciences and Roquefort Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does Roquefort Therapeutics compare to Verseon?

Verseon (LON:VSN) and Roquefort Therapeutics (LON:COIL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

In the previous week, Verseon's average media sentiment score of 0.00 equaled Roquefort Therapeutics'average media sentiment score.

Company Overall Sentiment
Verseon Neutral
Roquefort Therapeutics Neutral

1.8% of Roquefort Therapeutics shares are held by institutional investors. 36.3% of Roquefort Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Verseon has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Verseon's return on equity of 0.00% beat Roquefort Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
VerseonN/A N/A N/A
Roquefort Therapeutics -57,057.07%-18.71%-15.86%

Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VerseonN/AN/AN/A-£14.30N/A
Roquefort TherapeuticsN/AN/A-£1.52M-£20.24N/A

Summary

Verseon beats Roquefort Therapeutics on 4 of the 7 factors compared between the two stocks.

How does Roquefort Therapeutics compare to Scancell?

Roquefort Therapeutics (LON:COIL) and Scancell (LON:SCLP) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

1.8% of Roquefort Therapeutics shares are owned by institutional investors. Comparatively, 1.3% of Scancell shares are owned by institutional investors. 36.3% of Roquefort Therapeutics shares are owned by insiders. Comparatively, 13.2% of Scancell shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Scancell has a net margin of -116.98% compared to Roquefort Therapeutics' net margin of -57,057.07%. Scancell's return on equity of 128.87% beat Roquefort Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Roquefort Therapeutics-57,057.07% -18.71% -15.86%
Scancell -116.98%128.87%-45.28%

Roquefort Therapeutics has higher earnings, but lower revenue than Scancell. Scancell is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Roquefort TherapeuticsN/AN/A-£1.52M-£20.24N/A
Scancell£4.71M26.78-£6.75M-£0.55N/A

Roquefort Therapeutics has a beta of 0.05, indicating that its share price is 95% less volatile than the broader market. Comparatively, Scancell has a beta of 0.685, indicating that its share price is 32% less volatile than the broader market.

In the previous week, Scancell had 7 more articles in the media than Roquefort Therapeutics. MarketBeat recorded 7 mentions for Scancell and 0 mentions for Roquefort Therapeutics. Roquefort Therapeutics' average media sentiment score of 0.00 beat Scancell's score of -0.04 indicating that Roquefort Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Roquefort Therapeutics Neutral
Scancell Neutral

Summary

Roquefort Therapeutics and Scancell tied by winning 6 of the 12 factors compared between the two stocks.

How does Roquefort Therapeutics compare to Mereo BioPharma Group plc (MPH.L)?

Roquefort Therapeutics (LON:COIL) and Mereo BioPharma Group plc (MPH.L) (LON:MPH) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Roquefort TherapeuticsN/AN/A-£1.52M-£20.24N/A
Mereo BioPharma Group plc (MPH.L)N/AN/AN/A-£128.00N/A

Mereo BioPharma Group plc (MPH.L) has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Mereo BioPharma Group plc (MPH.L)'s return on equity of 0.00% beat Roquefort Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Roquefort Therapeutics-57,057.07% -18.71% -15.86%
Mereo BioPharma Group plc (MPH.L) N/A N/A N/A

1.8% of Roquefort Therapeutics shares are owned by institutional investors. 36.3% of Roquefort Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Roquefort Therapeutics' average media sentiment score of 0.00 equaled Mereo BioPharma Group plc (MPH.L)'saverage media sentiment score.

Company Overall Sentiment
Roquefort Therapeutics Neutral
Mereo BioPharma Group plc (MPH.L) Neutral

Summary

Mereo BioPharma Group plc (MPH.L) beats Roquefort Therapeutics on 4 of the 7 factors compared between the two stocks.

How does Roquefort Therapeutics compare to 4basebio?

Roquefort Therapeutics (LON:COIL) and 4basebio (LON:4BB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Roquefort Therapeutics has higher earnings, but lower revenue than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Roquefort TherapeuticsN/AN/A-£1.52M-£20.24N/A
4basebio£781K109.10-£9.84M-£116.00N/A

1.8% of Roquefort Therapeutics shares are held by institutional investors. Comparatively, 0.9% of 4basebio shares are held by institutional investors. 36.3% of Roquefort Therapeutics shares are held by insiders. Comparatively, 12.1% of 4basebio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Roquefort Therapeutics' average media sentiment score of 0.00 equaled 4basebio'saverage media sentiment score.

Company Overall Sentiment
Roquefort Therapeutics Neutral
4basebio Neutral

4basebio has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Roquefort Therapeutics' return on equity of -18.71% beat 4basebio's return on equity.

Company Net Margins Return on Equity Return on Assets
Roquefort Therapeutics-57,057.07% -18.71% -15.86%
4basebio N/A -231.29%-54.30%

4basebio has a consensus target price of GBX 1,400, suggesting a potential upside of 154.43%. Given 4basebio's stronger consensus rating and higher probable upside, analysts plainly believe 4basebio is more favorable than Roquefort Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Roquefort Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
4basebio
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Roquefort Therapeutics has a beta of 0.05, meaning that its share price is 95% less volatile than the broader market. Comparatively, 4basebio has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

Summary

Roquefort Therapeutics beats 4basebio on 7 of the 13 factors compared between the two stocks.

Get Roquefort Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for COIL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

COIL vs. The Competition

Export
MetricRoquefort TherapeuticsBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£26.55M£3.93B£7.25B£2.80B
Dividend YieldN/A3.65%2.53%6.27%
P/E Ratio-0.3113.62275.59367.15
Price / SalesN/A1,194.68579.5388,626.79
Price / Cash1.4939.4627.3027.87
Price / Book1.6317.2310.837.13
Net Income-£1.52M-£22.69M£3.50B£5.89B
7 Day Performance-15.95%-1.65%-1.26%0.05%
1 Month Performance-26.82%-7.98%-4.04%-0.49%
1 Year Performance-71.07%14.17%7.13%22.53%

Roquefort Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
COIL
Roquefort Therapeutics
N/AGBX 6.22
flat		N/A-71.1%£26.55MN/AN/A9
TILS
Tiziana Life Sciences
N/AN/AN/AN/A£113.85M-£3.60MN/A11
VSN
Verseon
N/AN/AN/AN/A£112.24MN/AN/AN/A
SCLP
Scancell
N/AGBX 9.32
-0.3%		N/A-7.0%£99.55M£4.71MN/A51
MPH
Mereo BioPharma Group plc (MPH.L)
N/AN/AN/AN/A£89.76MN/AN/A50

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:COIL) was last updated on 10/12/2026 by MarketBeat.com Staff.
From Our Partners
Urgent Attention to Executive Order #14363 (Buy This Stock Before Oct. 20th
Marc Chaikin, a 60-year Wall Street veteran whose past clients include George Soros and Steve Cohen, built a s...
Chaikin Analytics | Sponsoredtc pixel
Free Ticker: Anthropic's silent partner could soar after record $2 trillion IPO
Anthropic's IPO prospectus just leaked, revealing 261 pages tied to a record $2 trillion valuation. Beyond ...
Monument Traders Alliance | Sponsoredtc pixel
Tomorrow, Wall Street goes home for two days
Tomorrow at 4 PM Eastern, Wall Street closes for the weekend. Fund managers and billion-dollar accounts leave,...
Tim Sykes | Sponsoredtc pixel
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
How options let you do more with less capital
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel
Urgent: Invest In ‘Elon’s iPhone’ Before July 22nd
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Federal Reserve Reveals Disturbing New Plan To Control Your Money
Docket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...
Weiss Ratings | Sponsoredtc pixel